Drone strike razes Indian‑linked pharmaceutical complex
New Delhi. A Russian‑operated drone slammed into the Kusum Group’s manufacturing hub in Sumy, Ukraine, collapsing the main structure, killing an engineer and wounding multiple staff members. The assault, which hit the site several times, gutted the engineering wing and forced an immediate evacuation of the premises.
Early estimates put the damage at around Rs 400 crore, though the firm says a comprehensive audit is still pending. With such extensive destruction, the plant is expected to stay out of operation for an undetermined length of time.
Indian origins, Ukrainian presence
Kusum Group first entered the Ukrainian market in 1994, initially as a distributor of medicines sourced from India. By 2009 it had erected a full‑scale production complex in Sumy, complementing its 2007 manufacturing base back home in India. Today the conglomerate produces more than 50 generic medicines and supplies markets in Ukraine, Uzbekistan, Kazakhstan and the Philippines, positioning itself as a Ukrainian pharma player with Indian roots.
Operations survived war – until now
Despite the ongoing conflict, the Sumy plant continued to churn out essential drugs for patients across the region. The latest drone strike, however, has brought production to a halt and prompted the group to consider relocating vulnerable output to its Indian facilities.
Ukrainian President Volodymyr Zelenskyy condemned the incident, confirming that a drone barrage targeted the pharmaceutical complex and resulted in a fatality. The attack highlights the growing peril faced by civilian and commercial infrastructure in active war zones.
Broader implications
The loss of the Sumy plant jeopardises the supply of critical generic medicines in the region and raises serious questions about the resilience of cross‑border supply chains during armed conflicts. A thorough assessment will later reveal the full financial and operational impact on the Indian‑linked conglomerate.
